drugset / Trial / NCT03299738
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
Phase 1
Unknown
10 enrolled
Shanghai AbelZeta Ltd.
Tianjin Medical University Cancer Institute and Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
Timeline
- Start
- 2017-12
- Primary completion
- 2018-12
- Completion
- 2019-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C-CAR011 | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | C-CAR011 | Cell therapy | 5e+06 cells/kg | Intravenous |